ANI Pharmaceuticals (ANIP) provided an update on the status of the completion of its previously announced acquisition of Alimera Sciences (ALIM). ANI said in a statement: “We note the Alimera press release issued today. The Company continues to work in good faith toward closing of the acquisition. Any delay is a result of discussions regarding closing conditions, which the Company expects to resolve promptly.” Alimera Sciences, this morning announced that it has filed a lawsuit in the Delaware Court of Chancery to compel ANI “to fulfill its contractual obligation to close the transaction.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Announces Debt Clearance and Notes Sale
- ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes
- ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering
- ANI Pharmaceuticals announces proposed convertible senior notes offering
- ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering